Current Treatment Options for Metastatic Head and Neck Cancer

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02.

(2017) S. Schmitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

(2011) Athanassios Argiris et al.   JOURNAL OF CLINICAL ONCOLOGY

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

(2010) J Martinez-Trufero et al.   BRITISH JOURNAL OF CANCER

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

(2009) L. M. Knowles et al.   CLINICAL CANCER RESEARCH

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

(2008) B. A. Burtness et al.   ANNALS OF ONCOLOGY

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

(2008) C. Fakhry et al.   JNCI-Journal of the National Cancer Institute

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

(2008) Christine H. Chung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE